A novel combination of pozelimab and cemdisiran appears to be better than Ultomiris (ravulizumab) at controlling intravascular hemolysis —…
Articles by Margarida Maia, PhD
The European Commission has approved Roche’s PiaSky (crovalimab) to treat adults and adolescents with paroxysmal nocturnal hemoglobinuria (PNH), ages…
Using Empaveli (pegcetacoplan) during a new pregnancy led to a healthy outcome for a mother and her baby boy,…
Most of the adults with paroxysmal nocturnal hemoglobinuria (PNH) who switched from Soliris (eculizumab) to PiaSky (crovalimab)…
Individualized dosing of Empaveli (pegcetacoplan) may allow for a larger interval between doses in about 30% of adults with…
An independent appraisal committee voted that there was adequate evidence to show that adding danicopan to a C5 inhibitor may…
People in Japan using C5 inhibitors to treat their paroxysmal nocturnal hemoglobinuria (PNH) continue to experience symptoms like fatigue…
Almost 6 out of 10 people with paroxysmal nocturnal hemoglobinuria (PNH) living in the U.S. may be being given…
Danicopan, an experimental oral medication, continued to help control anemia when taken for up to 48 weeks by adults with…
This year, PNH News brought up-to-date coverage of the latest scientific and clinical research developments in paroxysmal nocturnal…